These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14626572)

  • 21. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The effect of recombinant erythropoietin on candidicidal activity of polymorphonuclear leukocytes in hemodialyzed patients].
    Bartůnková J; Sulková S; Cebecauer M
    Cas Lek Cesk; 1995 Dec; 134(23):756-9. PubMed ID: 8599817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human erythropoietin for late-onset anemia after allogeneic bone marrow transplantation.
    Fujimori Y; Kanamaru A; Saheki K; Mori A; Takatsuka H; Wada H; Okada M; Tamura S; Okamoto T; Takemoto Y; Kakishita E; Nagai K
    Int J Hematol; 1998 Feb; 67(2):131-6. PubMed ID: 9631579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The timing of pretransplant transfusions and renal allograft survival.
    Sanfilippo F; Spees EK; Vaughn WK
    Transplantation; 1984 Apr; 37(4):344-50. PubMed ID: 6369662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma.
    Silvestris F; Romito A; Fanelli P; Vacca A; Dammacco F
    Ann Hematol; 1995 Jun; 70(6):313-8. PubMed ID: 7632811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implications of recombinant erythropoietin therapy for renal transplantation.
    Ward HJ
    Am J Nephrol; 1990; 10 Suppl 2():44-7; discussion 48-52. PubMed ID: 2260618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of graft survival in pediatric and adolescent live donor kidney transplant recipients: a single center experience.
    El-Husseini AA; Foda MA; Shokeir AA; Shehab El-Din AB; Sobh MA; Ghoneim MA
    Pediatr Transplant; 2005 Dec; 9(6):763-9. PubMed ID: 16269048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
    Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
    Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of erythropoietin and its effects on blood lactate and 2, 3-diphosphoglycerate in premature neonates.
    Soubasi V; Kremenopoulos G; Tsantali C; Savopoulou P; Mussafiris C; Dimitriou M
    Biol Neonate; 2000 Nov; 78(4):281-7. PubMed ID: 11093007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoietin therapy in a pregnant post-renal transplant patient.
    Al Shohaib S
    Nephron; 1999 Jan; 81(1):81-3. PubMed ID: 9884425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing cadaver kidney transplantation outcome in the cyclosporine era. The North Italy Transplant Program (NITp).
    Clin Transpl; 1988; ():131-45. PubMed ID: 3154466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect of recombinant human erythropoietin (rHu-EPO) on the autonomic nervous system in patients hemodialyzed for chronic kidney failure].
    Pacyk G; Grzeszczak W
    Pol Arch Med Wewn; 1997 Jan; 97(1):22-9. PubMed ID: 9235548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hemostatic changes associated with recombinant human erythropoietin (rHu Epo) treatment].
    Vinhas J; Assis P; Oliveira C; Crespo F; Prata MM
    Acta Med Port; 1991; 4(1):9-12. PubMed ID: 2048426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin production after kidney transplantation.
    Gaciong Z; Koziak K; Jarzyło I; Ludwicki K; Malanowska S; Paczek L; Szmidt J; Wałaszewski J; Lao M
    Ann Transplant; 1996; 1(1):29-33. PubMed ID: 9869934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effect of hemodialysis on levels of beta-endorphin in serum of patients with chronic renal failure treated with erythropoietin].
    Burak W; Grzeszczak W; Trelewicz P; Zukowska-Szczechowska E
    Przegl Lek; 1996; 53(2):54-7. PubMed ID: 8754321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multi-factor analysis of kidney regraft outcomes.
    Gjertson DW
    Clin Transpl; 2002; ():335-49. PubMed ID: 12971460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perioperative erythropoietin efficacy in renal transplantation.
    Mohiuddin MK; El-Asir L; Gupta A; Brown A; Torpey N; Ward M; Talbot D; Ahmed S
    Transplant Proc; 2007; 39(1):132-4. PubMed ID: 17275489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
    Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
    Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of recombinant human erythropoietin on kinetics of alloantibodies in patients awaiting renal allograft].
    Boratyńska M; Szewczyk Z; Nowakowska B; Baldy-Chudzik K; Pytel A
    Przegl Lek; 1995; 52(9):424-7. PubMed ID: 8834641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of renal transplantation in patients treated with erythropoietin.
    Linde T; Wahlberg J; Wikström B; Danielson BG
    Clin Nephrol; 1992 May; 37(5):260-3. PubMed ID: 1606776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.